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Abstract. The risk factors for development of paradoxical 
response were studied in a cohort of 104 patients with culture-
documented Mycobacterium tuberculosis infection. Paradoxical 
deterioration occurred in 16 (15.4%) patients (case group) 
during antituberculosis therapy, involving lungs and pleura 
(n=4), spine and paraspinal tissue (n=5), intracranium (n=3), 
peritoneum (n=2), bone and joint (n=1), and lymph node (n=1). 
The median time from commencement of treatment to 
paradoxical deterioration was 56 days (range, 20– 109 days). 
Compared with 53 patients without clinical deterioration after 
antituberculosis therapy (control group), patients with 
paradoxical response were more likely to have extrapulmonary 
involvement (62.5% vs. 17.0%; P<0.05) at initial diagnosis, to 
have lower baseline lymphocyte counts (672±315 cells/μ l vs. 
1,328±467 cells/μ l; P<0.001), and to exhibit a greater surge in 
lymphocyte counts (627±465 cells/μ l vs. 225±216 cells/μ l; 
P<0.05) during paradoxical response. Further studies on 
lymphocyte subsets and cytokine levels would be useful in 





Paradoxical response during antituberculosis therapy is a well-
known phenomenon in HIV-negative patients [1]. It has been 
observed in 6– 30% of patients receiving antituberculosis 
therapy for tuberculous pleural effusion and lymphadenitis [2, 3, 
4]. Paradoxical worsening of pre-existing pulmonary and 
extrapulmonary tuberculosis has been increasingly reported in 
HIV-positive patients, which produces a diagnostic challenge to 
caring infectious disease and respiratory physicians [5, 6, 7, 8, 
9, 10, 11, 12, 13, 14, 15, 16]. In recent studies, this condition 
was found in 11– 36% of patients receiving highly active 
antiretroviral therapy (HAART) [7, 8, 15]. Although the 
pathogenesis of paradoxical response has not been clearly 
elucidated, it appeared more frequently in patients with 
significant reductions in viral load and increases in CD4+ 
lymphocyte counts after HAART, especially when HAART was 
administered within 2 months of antituberculosis therapy [15]. 
Therefore, appropriate timing of initiation of HAART and 
antituberculosis therapy may reduce the phenomenon. 
However, a systematic analysis of the incidence, clinical 
spectrum and risk factors in this clinical entity in HIV-negative 
patients is lacking. 
In this article, we report a cohort of 104 HIV-negative patients 
with culture-documented tuberculosis in whom paradoxical 
deterioration occurred during antituberculosis therapy. 
Extrapulmonary involvement at initial diagnosis and lower 
baseline lymphocyte counts were associated with the 
development of paradoxical response. 
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<heading1>Materials and Methods 
<heading2>Study Design and Patients 
All clinical data were collected prospectively over a 24-month 
period (1 July 2000– 30 June 2002) on patients referred for 
infectious disease consultation in Queen Mary Hospital, a 
1,350-bed tertiary teaching hospital in Hong Kong. Patients who 
presented with clinical features suggestive of tuberculosis were 
included in the study. 
 
<heading2>Diagnosis and Treatment of Mycobacterium 
tuberculosis Infection 
Investigations for Mycobacterium tuberculosis, including culture 
and examination of smears for acid-fast bacilli, in relevant 
clinical specimens of all patients with suspected tuberculosis 
were performed. Polymerase chain reaction to detect 
Mycobacterium tuberculosis (TB-PCR) was performed on 
pulmonary and extrapulmonary specimens in the following 
clinical settings: (i) patients with typical radiological changes 
compatible with pulmonary tuberculosis; (ii) patients with 
radiological changes due to prior tuberculosis but presenting 
with new pulmonary infiltrates; (iii) patients with community-
acquired pneumonia unresponsive to appropriate antibiotic 
therapy; (iv) patients undergoing invasive procedures such as 
image-guided or surgical drainage and biopsy for sterile sites in 
the work-up for extrapulmonary tuberculosis. Histological 
examination for Mycobacterium tuberculosis was also 
performed if clinically indicated. 
Preliminary diagnosis of Mycobacterium tuberculosis was based 
on positive smear for acid-fast bacilli, TB-PCR, or tissue 
histology results during the initial work-up. A definitive diagnosis 
of tuberculosis was made by positive culture results. 
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Antituberculosis therapy including isoniazid, rifampicin, 
pyrazinamide, and ethambutol was administered to patients 
with a preliminary or definitive diagnosis of tuberculosis, or, if 
clinical suspicion of tuberculosis was high, therapy was 
administered empirically. 
 
<heading2>Development of Paradoxical Response 
Patients were monitored for development of paradoxical 
deterioration during antituberculosis therapy. The definition of 
paradoxical response has been described previously [1]. It is 
defined as the clinical or radiological worsening of pre-existing 
tuberculous lesions or the development of new lesions not 
attributable to the normal course of disease in a patient who 
initially improves with antituberculosis therapy and in whom the 
onset of paradoxical response occurs at least 2 weeks after the 
initiation of treatment. Patients who presented with progressive 
tuberculosis without initial clinical improvement, whose 
compliance with antituberculosis therapy could not be 
ascertained, or in whom an alternative diagnosis was made 
were excluded. The time to development of paradoxical 
response is defined as the interval between the initiation of 
antituberculosis therapy and the onset of paradoxical response 
as defined above. 
 
<heading2>Monitoring of Absolute Lymphocyte Counts 
Baseline lymphocyte counts were measured in all patients 
recruited in this study. Lymphocyte counts were also recorded 
in patients during paradoxical deterioration and at the end of 
therapy in those patients who remained uneventful during 
antituberculosis therapy. Both the absolute values and the serial 
change in lymphocyte counts from baseline were analysed in 
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patients with or without paradoxical deterioration. 
 
<heading2>Identification of Immunocompromised Hosts 
HIV antibody was checked, after written consent, in patients 
with a clinical diagnosis of extrapulmonary tuberculosis or if 
clinically indicated. Patients receiving immunosuppressive 
therapy (systemic steroids, cytotoxic agents, a combination of 
steroids and cytotoxic agents, or irradiation) or diagnosed with 
HIV infection were noted and excluded from the analysis of the 
change in lymphocyte counts. 
 
<heading2>Statistical Analysis 
The characteristics of patients with culture-documented 
tuberculosis with or without paradoxical deterioration during 
antituberculosis therapy were compared. The chi-square test 
was used for categorical variables. Continuous variables were 
tested by the Student's t test. A P value of <0.05 was 
considered significant. A statistical package (SPSS 10.0; SPSS, 




During the 2-year study period, there were 5,315 inpatient 
infectious disease consultations from various clinical specialties. 
One hundred fifty-five patients with clinical symptoms and signs 
suggestive of tuberculosis were recruited in this study. 
 
<heading2>Diagnosis and Treatment of Mycobacterium 
tuberculosis Infection 
A total of 127 of 155 (82%) patients received antituberculosis 
therapy in this cohort, in which treatment was (i) given 
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empirically in 10 patients, (ii) based on positive results in initial 
work-up in 103 patients, and (iii) administered after positive 
culture results in 14 patients. One hundred eighteen of the 127 
(93%) patients had completed the treatment. Nine patients 
defaulted follow-up after initiation of therapy. 
 
<heading2>Development of Paradoxical Response 
Of the 118 patients who completed antituberculosis therapy, 
104 with culture documentation of Mycobacterium tuberculosis 
were further analyzed for development of paradoxical 
deterioration during antituberculosis therapy. Fifty-one of the 
104 patients experienced clinical deterioration requiring 
hospitalization. Culture results for Mycobacterium tuberculosis 
were not yet available at the time of deterioration in 44 (86.3%) 
patients, among whom TB-PCR was positive in 35 (80%). 
Thirty-five of the 51 (68.6%) patients were diagnosed to have 
deterioration due to problems other than paradoxical response: 
15 had community-acquired infections, 10 had liver impairment 
and gouty attack related to antituberculosis drugs, 6 had 
malignancy, 2 had cerebrovascular accident, and 2 had 
nonspecific abdominal pain. 
Paradoxical response occurred in 16 of 51 (31.4%) patients 
presenting with clinical deterioration after antituberculosis 
therapy. There were nine males and seven females, and the 
mean age was 48.1 years. The median time to onset of 
paradoxical deterioration was 56 days (range, 20– 109 days) 
after the initiation of antituberculosis therapy among these 16 
patients. Paradoxical response developed in lungs and pleura in 
four patients, in the spine and paraspinal soft tissue in five 
patients, in the intracranium in three patients, in the peritoneum 
in two patients, in the left hip in one patient, and in the right 
7 
supraclavicular lymph nodes in one patient (Table 1). 
Development of new lesions in anatomical sites other than 
those observed at initial presentation was observed in five 
(31.2%) patients. Of these 16 patients, results of culture for 
Mycobacterium tuberculosis were not available at the time of 
worsening of signs and symptoms in 10 (62.5%) patients, but 
TB-PCR was positive in 6 (60%) of them. The initial 
Mycobacterium tuberculosis isolates in these 16 patients with 
paradoxical response were tested for susceptibility to isoniazid, 
rifampicin, ethambutol, and streptomycin. One strain was 
resistant to streptomycin and sensitive to the other drugs, while 
all other strains were susceptible to all drugs tested. Smears for 
acid-fast bacilli and cultures obtained from sputum, pleural fluid, 
cerebrospinal fluid, and surgical specimens during paradoxical 
deterioration were all negative. Treatment of the paradoxical 
response included administration of steroids in 6 (37.5%) 
patients and surgical intervention in 10 (62.5%). Residual 
functional deficits occurred in 6 (37.5%) patients. 
Compared with 53 patients without clinical deterioration after 
antituberculosis therapy (control group), there was no difference 
in age, sex, and underlying comorbidity in patients with 
paradoxical deterioration (Table 2). There was no HIV-infected 
patient in either group. Extrapulmonary tuberculosis as an initial 
manifestation was found in a significantly higher proportion of 
patients with paradoxical response (81.2%) than in those 
without clinical deterioration (24.5%). Patients with paradoxical 
deterioration had a significantly lower lymphocyte count at 
baseline (672±315 cells/μ l) than those without deterioration 
(1,328±467 cells/μ l). A surge in absolute lymphocyte counts 
was observed in patients during paradoxical deterioration, with 
a mean difference in lymphocyte counts between baseline and 
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at paradoxical response of 627±465 cells/μ l. Serial lymphocyte 
counts were also available in the control group, but an increase 
in absolute lymphocyte counts was not observed. When serial 
changes in lymphocyte counts were further analysed after 
exclusion of six hosts with immunosuppressive conditions 
(autoimmune diseases in 4, bronchogenic carcinoma in 1, and 
haemoglobin H disease in 1 patient in the control group), a 
statistically significant result was found. 
 
<heading1>Discussion 
Paradoxical response was not an uncommon phenomenon in 
this study, occurring in 11.1% of patients with a clinical 
diagnosis of tuberculosis infection, 15.4% of patients with 
culture documentation of Mycobacterium tuberculosis, and 
31.4% of patients who deteriorated clinically after receiving 
antituberculosis therapy. Significant medical and surgical 
intervention was required in these patients, including use of 
steroids in one-third of them. Thirty-seven percent of patients 
were complicated by residual functional deficits. 
In the present report, paradoxical response developed more 
commonly in patients with extrapulmonary tuberculosis, which 
concurs with the findings in the literature that 101 of 122 
(82.8%) episodes of paradoxical deterioration were associated 
with extrapulmonary tuberculosis in non-HIV-infected patients 
[1]. The central nervous system remains the most common site 
of presentation, affected in 50% of the patients with paradoxical 
deterioration in the present study. In contrast to the recent 
literature review [1], the present series showed a high 
propensity for spinal and paraspinal involvement: about one-
third of patients had paradoxical response in these areas. The 
appearance of new lesions in anatomical sites that were 
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unaffected at initial presentation was observed in 5 (31.2%) 
patients. This suggests that attending physicians should be alert 
to this possibility. 
Although the clinical spectrum of paradoxical deterioration 
during antituberculosis therapy in both HIV-negative and HIV-
positive patients has recently been described [1, 14], studies on 
risk factors for development of paradoxical response are scarce 
and limited exclusively to HIV-positive patients [8, 15]. Of 82 
episodes of paradoxical response in 76 HIV-positive patients, 
paradoxical worsening occurred in 7 (8.5%) episodes. Patients 
complicated by paradoxical deterioration were more likely to 
have both pulmonary and extrapulmonary tuberculosis. Those 
patients with paradoxical response appeared to have a lower 
median initial CD4+ count (69 cells/μ l) when compared to 
those without paradoxical deterioration (154 cells/μ l). However, 
the difference was not statistically significant due to the small 
number of cases [8]. 
In our present report, extrapulmonary tuberculosis, with or 
without pulmonary involvement, and low baseline lymphocyte 
counts were demonstrated to be significantly associated with 
subsequent development of paradoxical responses in HIV-
negative patients leading to hospital admission. An upsurge in 
lymphocyte counts was observed in patients during paradoxical 
deterioration. The mean difference in lymphocyte counts was 
significantly greater in patients with paradoxical response than 
those without. Such findings further strengthened our previous 
observation that a concomitant increase in absolute lymphocyte 
counts occurred during paradoxical deterioration in both HIV-
negative and HIV-positive individuals [1, 17, 18]. However, it 
must be emphasised that the number of circulating lymphocytes 
does not always reflect the numbers of lymphocytes in the 
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involved tissues or their in vivo functional status. For instance, 
in our previous reported case of a patient with Pneumocystis 
carinii pneumonia undergoing steroid withdrawal, the 
lymphocyte count surged to a very high level and then dropped 
to a low level within the same day due to extremely severe 
immunorestitution, which occurs when the lymphocytes all 
migrate to the site of restitution to produce severe damage [19]. 
In cases 2, 10, 14, and 15 (in Table 1), the lymphocyte counts 
were apparently static or depressed despite paradoxical 
deterioration, and thus the lack of an upsurge in lymphocyte 
counts does not exclude the diagnosis. 
The clinical severity of paradoxical deterioration is dependent 
on the exactness and appropriateness of immune recovery. An 
overwhelming and exaggerated immune recovery may lead to 
excessive immunopathological damage at the tissue level [19, 
20]. Further studies on lymphocyte subsets and cytokine levels 
would be useful in understanding the exact immunological 
mechanisms involved in immunorestitution. 
Despite gains made in understanding the risk factors for 
development of paradoxical response, diagnosis of this 
condition remains difficult in the clinical setting. The diagnosis 
can be ascertained only when other differential diagnoses or 
reasons are excluded, such as secondary community-acquired 
or nosocomial infections, inadequate antituberculosis therapy 
due to drug resistance, poor compliance, and side-effects of 
antituberculosis therapy. Since all patients received first-line 
antituberculosis therapy, including isoniazid, rifampicin, 
pyrazinamide, and ethambutol as initial therapy, primary or 
acquired drug resistance should have been excluded before 
paradoxical deterioration was diagnosed. Although multidrug-
resistant Mycobacterium tuberculosis has become an emerging 
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problem in certain parts of the world [21], its overall prevalence 
remains low (2.1%) in Hong Kong [22]. In our present report, 
only 1 of 16 strains isolated from patients with paradoxical 
deterioration was resistant to just a single drug, i.e. 
streptomycin. However, using the rpoB gene sequence, real-
time PCR and fluorimetry for rapid detection of mutations 
associated with rifampicin and isoniazid resistance have been 
performed in the laboratory setting [23, 24]. The molecular test 
would be beneficial in regions where the prevalence of 
multidrug resistance is high. 
The clinical spectrum of paradoxical deterioration may be 
confounded in this study. Since we focused on moderate to 
severe paradoxical deterioration requiring hospital admission, 
patients with relatively asymptomatic radiological worsening that 
does not warrant admission may have been missed. However, it 
may not be possible to diagnose paradoxical response in an 
outpatient setting without performing a complete physical 
examination and investigations to exclude other possibilities. 
Therefore, further investigation and collaboration with a 
community chest physician is warranted. 
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